ArticleLeukemia & lymphoma2017
Impact of metformin on the progression of MGUS to multiple myeloma.
Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis.Annals of Saudi medicinePooled it
- Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.Blood cancer journal · 2026Article
- A nested case-control study of monoclonal gammopathy of undetermined significance in the Multiethnic Cohort study.Blood advances · 2026Article
- Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.Current obesity reports · 2025Review
- Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression.Leukemia · 2025Article
- Cumulative Excess Body Mass Index and MGUS Progression to Myeloma.JAMA network open · 2025Article
- Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.JNCI cancer spectrum · 2024Article
- Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients.Cancers · 2024Review
- It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.Blood advances · 2023Review
- Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.Blood cancer journal · 2023Article
- Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.Biomolecules · 2023Review
- Obesity and myeloma: Clinical and mechanistic contributions to disease progression.Frontiers in endocrinology · 2023Review
- Article
- Metformin and Cancer, an Ambiguanidous Relationship.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo.Translational oncology · 2022Article
- Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?Advances in hematology · 2021Review
- Influence of metformin on HIF-1 pathway in multiple myeloma.Pharmacological reports : PR · 2020Article
- Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis.Translational cancer research · 2020Article
- Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution.JNCI cancer spectrum · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.